Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 7/2017

Open Access 01-07-2017 | Review

The Changing Landscape of Alopecia Areata: The Translational Landscape

Authors: Etienne C. E. Wang, Angela M. Christiano

Published in: Advances in Therapy | Issue 7/2017

Login to get access

Abstract

Recent genetic and preclinical studies have increased our understanding of the immunopathogenesis of alopecia areata (AA). This has allowed expedited development of targeted therapies for the treatment of AA, and a paradigm shift in our approach and understanding of autoimmunity and the hair follicle. The synergy between preclinical studies, animal models, and translational studies has led to unprecedented advances in the treatment options for AA, ultimately benefiting patients who have had little recourse. In this review, we summarize the scientific field of contemporary AA research, and look forward to potential new technologies and developments.
Literature
1.
Safavi KH, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70(7):628–33.CrossRefPubMed
2.
Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397–403.PubMedPubMedCentral
3.
Petukhova L, Christiano AM. The genetic architecture of alopecia areata. J Investig Dermatol Symp Proc. 2013;16(1):S16–22.CrossRefPubMed
4.
5.
Colombe BW, et al. HLA class II antigen associations help to define two types of alopecia areata. J Am Acad Dermatol. 1995;33(5 Pt 1):757–64.PubMed
6.
Barahmani N, et al. Major histocompatibility complex class I chain-related gene A polymorphisms and extended haplotypes are associated with familial alopecia areata. J Invest Dermatol. 2006;126(1):74–8.CrossRefPubMed
7.
Moftah NH, et al. ULBP3: a marker for alopecia areata incognita. Arch Dermatol Res. 2016;308(6):415–21.CrossRefPubMed
8.
Betz RC, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun. 2015;6:5966.CrossRefPubMedPubMedCentral
9.
Petukhova L, Christiano AM. Functional interpretation of genome-wide association study evidence in alopecia areata. J Invest Dermatol. 2016;136(1):314–7.CrossRefPubMedPubMedCentral
10.
11.
Kuwano Y, et al. Serum chemokine profiles in patients with alopecia areata. Br J Dermatol. 2007;157(3):466–73.CrossRefPubMed
12.
Sadeghi S, et al. Study of Th1/Th2 balance in peripheral blood mononuclear cells of patients with alopecia areata. Acta Microbiol Immunol Hung. 2015;62(3):275–85.CrossRefPubMed
13.
Suarez-Farinas M, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol. 2015;136(5):1277–87.CrossRefPubMed
14.
15.
Paus R, Bertolini M. The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. J Investig Dermatol Symp Proc. 2013;16(1):S25–7.CrossRefPubMed
16.
Wang EH, et al. Identification of autoantigen epitopes in alopecia areata. J Invest Dermatol. 2016;136(8):1617–26.
17.
Tobin DJ, et al. Autoantibodies to hair follicles in C3H/HeJ mice with alopecia areata-like hair loss. J Invest Dermatol. 1997;109(3):329–33.CrossRefPubMed
18.
Leung MC, et al. Trichohyalin is a potential major autoantigen in human alopecia areata. J Proteome Res. 2010;9(10):5153–63.CrossRefPubMed
19.
Sundberg JP, et al. C3H/HeJ mouse model for alopecia areata. J Invest Dermatol. 1995;104(5 Suppl):16S–7S.CrossRefPubMed
20.
McElwee KJ, et al. Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest Dermatol. 1998;111(5):797–803.CrossRefPubMed
21.
Wang EH, et al. Transfer of alopecia areata to C3H/HeJ mice using cultured lymph node-derived cells. J Invest Dermatol. 2015;135(10):2530–2.CrossRefPubMed
22.
Gilhar A, Keren A, Paus R. A new humanized mouse model for alopecia areata. J Investig Dermatol Symp Proc. 2013;16(1):S37–8.CrossRefPubMed
23.
24.
Estefan J, et al. Alopecia areata–Part II: diagnosis and pathology. Skinmed. 2015;13(2):121–6.PubMed
25.
Tosti A, et al. The role of scalp dermoscopy in the diagnosis of alopecia areata incognita. J Am Acad Dermatol. 2008;59(1):64–7.CrossRefPubMed
26.
Ardigo M, et al. Reflectance confocal microscopy of the yellow dot pattern in alopecia areata. Arch Dermatol. 2011;147(1):61–4.CrossRefPubMed
27.
Hordinsky M, Donati A. Alopecia areata: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):231–46.CrossRefPubMed
28.
Hordinsky MK. Current treatments for alopecia areata. J Investig Dermatol Symp Proc. 2015;17(2):44–6.CrossRefPubMed
29.
Pieri L, Guglielmelli P, Vannucchi AM. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol. 2015;90(1):82–3.CrossRefPubMed
30.
Higgins E, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015;135(2):551–3.CrossRefPubMed
31.
Kennedy Crispin M, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776.CrossRefPubMedPubMedCentral
32.
33.
Patel H, et al. Association of cytotoxic T-lymphocyte antigen 4 (CTLA4) and thyroglobulin (TG) genetic variants with autoimmune hypothyroidism. PLoS One. 2016;11(3):e0149441.CrossRefPubMedPubMedCentral
34.
Benhatchi K, et al. CTLA4 exon1 A49G polymorphism in Slovak patients with rheumatoid arthritis and Hashimoto thyroiditis-results and the review of the literature. Clin Rheumatol. 2011;30(10):1319–24.CrossRefPubMed
35.
Repnik K, Potocnik U. CTLA4 CT60 single-nucleotide polymorphism is associated with Slovenian inflammatory bowel disease patients and regulates expression of CTLA4 isoforms. DNA Cell Biol. 2010;29(10):603–10.CrossRefPubMed
36.
Megiorni F, et al. Cytotoxic T-lymphocyte antigen 4 (CTLA4) +49AG and CT60 gene polymorphisms in alopecia areata: a case-control association study in the Italian population. Arch Dermatol Res. 2013;305(7):665–70.CrossRefPubMed
37.
Nusslein HG, et al. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol. 2016;34(3):489–99.PubMed
38.
Petukhova L, et al. The genetics of alopecia areata: what’s new and how will it help our patients? Dermatol Ther. 2011;24(3):326–36.CrossRefPubMed
39.
Ali A, Martin JMT. Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. J Drugs Dermatol. 2010;9(1):62–4.PubMed
40.
Lattouf C, et al. Treatment of alopecia areata with simvastatin/ezetimibe. J Am Acad Dermatol. 2015;72(2):359–61.CrossRefPubMed
41.
Loi C, Starace M, Piraccini BM. Alopecia areata (AA) and treatment with simvastatin/ezetimibe: experience of 20 patients. J Am Acad Dermatol. 2016;74(5):e99–100.CrossRefPubMed
42.
Moreira FT, et al. Effects of two lipid lowering therapies on immune responses in hyperlipidemic subjects. Life Sci. 2014;98(2):83–7.CrossRefPubMed
43.
Bolduc C, Bissonnette R. Safety and efficacy of adalimumab for the treatment of severe alopecia areata: case series of three patients. J Cutan Med Surg. 2012;16(4):257–60.CrossRefPubMed
44.
Hernandez MV, et al. Development of alopecia areata after biological therapy with TNF-alpha blockers: description of a case and review of the literature. Clin Exp Rheumatol. 2009;27(5):892–3.PubMed
45.
46.
Freyschmidt-Paul P, et al. Interferon-gamma-deficient mice are resistant to the development of alopecia areata. Br J Dermatol. 2006;155(3):515–21.CrossRefPubMed
47.
Freyschmidt-Paul P, et al. The functional relevance of the type 1 cytokines IFN-gamma and IL-2 in alopecia areata of C3H/HeJ mice. J Investig Dermatol Symp Proc. 2005;10(3):282–3.CrossRefPubMed
48.
Pham MN, von Herrath MG, Vela JL. Antigen-specific regulatory T cells and low dose of IL-2 in treatment of type 1 diabetes. Front Immunol. 2015;6:651.PubMed
49.
Castela E, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014;150(7):748–51.CrossRefPubMed
50.
Guttman-Yassky E, et al. Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. J Allergy Clin Immunol. 2016;137(1):301–4.CrossRefPubMed
Metadata
Title
The Changing Landscape of Alopecia Areata: The Translational Landscape
Authors
Etienne C. E. Wang
Angela M. Christiano
Publication date
01-07-2017
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 7/2017
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-017-0540-9

Other articles of this Issue 7/2017

Advances in Therapy 7/2017 Go to the issue

Review

The Changing Landscape of Alopecia Areata: An Introduction

Review

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin

Original Research

Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients

Original Research

Minimal Device Encrustation on Vesair Intravesical Balloons in the Treatment of Stress Urinary Incontinence: Analysis of Balloons Removed from Women in the SOLECT Trial

Review

When Science is Not Enough: A Framework Towards More Customer-Focused Drug Development

Review

Advances in Clinical Cardiology 2016: A Summary of the Key Clinical Trials

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits